argenx SE
VYVGART
anti-acetylcholine receptor antibody negative gMG
Resolved
60days ago
Approval decision · May 8, 2026
What's at stake
A final FDA approval decision on VYVGART for anti-acetylcholine receptor antibody negative gMG is expected May 8, 2026.
Primary source
· SEC 6-K
verified 12h ago
“argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) approved a label expansion fo”